We're off to the races!

Octapharma USA Announces FDA Approval of wilate(R) – the First Replacement Therapy Developed Specifically for von Willebrand Dis

Octapharma USA Announces FDA Approval of wilate(R) – the First Replacement Therapy Developed Specifically for von Willebrand Disease Milestone Marks Swiss Company’s Entrance into the U.S. Blood Coagulation MarketHOBOKEN, N.J., Dec. 7 /PRNewswire/ — Octapharma USA today announced the U.S. Food and Drug Administration has approved wilate® for the treatment of spontaneous and trauma-induced bleeding episodes […]

en_USEnglish